In today’s climate, government and whistleblower allegations of False Claims Act (FCA) violations pose an increasingly significant threat to many corporations. State attorneys general are conducting more frequent investigations and asserting claims under state laws modeled around the federal False Claims Act. More qui tam actions are being filed each year as the opportunity for and incidences of significant whistleblower monetary awards increase.
Our team – which includes more than a dozen former federal prosecutors and Assistant U.S. Attorneys, several of whom held leadership positions in these roles – represent companies and their officers, directors and employees in complex criminal fraud investigations, internal investigations, and civil and qui tam litigation. We work across numerous industries, including government contractors, healthcare, defense, higher education, financial consulting, technology and life sciences.
Goodwin regularly represents pharmaceutical companies, medical device companies, manufacturers of durable medical equipment, hospitals, healthcare delivery organizations, medical laboratories, nursing homes, medical clinics – as well as these organizations’ officers, directors, and employees – in FCA-related litigation and investigations matters. We have extensive experience defending clients in healthcare fraud investigations brought by the Department of Justice, state Attorneys General, the U.S. Department of Health and Human Services, the Food & Drug Administration, the Federal Trade Commission, and a number of other government agencies. These investigations have involved a wide range of healthcare fraud allegations, including Medicare, Medicaid, and insurance carrier fraud; kickbacks; off-label promotion of products; violations of the Food, Drug and Cosmetic Act; HIPAA violations; and nursing home abuse. We also conduct internal investigations into potential healthcare fraud for our clients and assist them in designing compliance programs.